Sekisui Chemical Co., Ltd. (4204.T) Bundle
Curious whether Sekisui Chemical (4204.T) is a buy, hold or sell? This deep-dive teases the answers by unpacking headline figures-FY2025 net sales of ¥1.297 trillion (up 3.28%) and Q1 net sales of ¥305.15 billion (+2.1%) alongside operating profit of ¥107.95 billion for the year (operating margin ~8.3% vs 7.5% prior) even as management trims its full-year operating income forecast from ¥115 billion to ¥110 billion and cuts projected net income to ¥72 billion; you'll see how a conservative balance sheet-total assets ¥1.29 trillion, liabilities ¥465.80 billion, stockholders' equity ¥795.76 billion and a low debt-to-equity of 0.14-pairs with strong cash generation (operating cash flow ¥122.64 billion, free cash flow ¥61.71 billion, cash ¥103.57 billion, current ratio 1.5) and valuation metrics (market cap ~¥1.06 trillion, P/S 0.82, EPS ¥143.67, P/E ~19, dividend yield ~2.9%) while weighing risks from FX, softer EV-driven HPP demand and housing starts against investments-capex rising to ¥105 billion and R&D to ¥45 billion-to drive growth in Electronics, Mobility and Industrial; read on to see how profitability, liquidity, leverage, valuation and sustainability credentials (13 years in the DJSI World Index) translate into actionable insights for investors
Sekisui Chemical Co., Ltd. (4204.T) - Revenue Analysis
Sekisui Chemical reported steady top-line growth in the fiscal year ending March 31, 2025, supported by resilient demand across its businesses despite profit forecast revisions. Key reported figures and guidance are summarized below for quick investor reference.
- Fiscal year (FY) net sales: ¥1.297 trillion - +3.28% YoY.
- Q1 FY2025 net sales: ¥305.15 billion - +2.1% YoY.
- Q1 FY2025 operating profit: ¥21.22 billion - +5.1% YoY (record-high net sales in Q1).
- Revised full-year operating income forecast: ¥110.0 billion (previous: ¥115.0 billion).
- Revised full-year net income forecast: ¥72.0 billion (previous: ¥82.0 billion).
- Dividend forecast maintained: ¥80 per share.
| Metric | Amount (¥) | YoY / Revision |
|---|---|---|
| FY (ending Mar 31, 2025) Net Sales | 1,297,000,000,000 | +3.28% |
| Q1 FY2025 Net Sales | 305,150,000,000 | +2.10% |
| Q1 FY2025 Operating Profit | 21,220,000,000 | +5.10% |
| Full-year Operating Income (revised) | 110,000,000,000 | Down from ¥115,000,000,000 |
| Full-year Net Income (revised) | 72,000,000,000 | Down from ¥82,000,000,000 |
| Dividend Forecast | ¥80 / share | Unchanged |
- Top-line momentum: FY sales growth of 3.28% indicates continued demand stability across core segments.
- Profitability pressure: management trimmed operating and net income forecasts (operating income down ¥5.0bn vs prior forecast; net income down ¥10.0bn), signaling cost or mix challenges despite higher sales.
- Dividend policy: maintaining ¥80/share supports yield continuity and investor confidence amid revised earnings.
- Quarterly dynamics: Q1 delivered record-high net sales with operating profit rising faster than sales percentage-wise, suggesting some short-term margin recovery.
Further background on shareholder composition and investor interest can be found here: Exploring Sekisui Chemical Co., Ltd. Investor Profile: Who's Buying and Why?
Sekisui Chemical Co., Ltd. (4204.T) - Profitability Metrics
- Operating profit for the fiscal year ending March 31, 2025: ¥107.95 billion (up 14.4% YoY).
- Operating profit margin FY2025: ~8.3% (FY2024: 7.5%).
- Net income FY2025: ¥60.10 billion (down 11.6% YoY).
- Net profit margin FY2025: ~4.6% (FY2024: 5.4%).
- Return on equity (TTM): 8.89%.
- Gross profit margin: ~32% (stable year-over-year).
| Metric | FY2024 | FY2025 |
|---|---|---|
| Revenue (estimated from margins) | ¥1,258.4 billion | ¥1,301.8 billion |
| Operating Profit | ¥94.38 billion | ¥107.95 billion |
| Operating Profit Margin | 7.5% | 8.3% |
| Net Income | ¥67.94 billion | ¥60.10 billion |
| Net Profit Margin | 5.4% | 4.6% |
| Gross Profit Margin | ~32% | ~32% |
| Return on Equity (TTM) | - | 8.89% |
- Interpretation for investors: improved operating efficiency (higher operating margin and operating profit growth) contrasts with lower bottom-line profitability (net income decline and compressed net margin), signaling higher non-operating costs, taxes, or one-off items in FY2025.
- Stable gross margin (~32%) suggests the core businesses maintained pricing power and cost control despite margin pressure downstream.
- ROE of 8.89% indicates moderate capital efficiency; combined with rising operating profit, this may support valuation re-rating if net-margin headwinds are resolved.
- For strategic context and corporate direction, see: Mission Statement, Vision, & Core Values (2026) of Sekisui Chemical Co., Ltd.
Sekisui Chemical Co., Ltd. (4204.T) - Debt vs. Equity Structure
Sekisui Chemical's balance-sheet composition as of March 31, 2025 shows a conservative leverage posture and a solid equity base. Key headline figures:| Metric | Amount (¥) | Notes |
|---|---|---|
| Total assets | ¥1.29 trillion | As of March 31, 2025 |
| Total liabilities | ¥465.80 billion | Includes all short- and long-term obligations |
| Stockholders' equity | ¥795.76 billion | Strong capital base |
| Total debt (FY2024) | ¥120.72 billion | Prior fiscal year |
| Total debt (FY2025) | ¥111.97 billion | Decline vs FY2024 |
| Debt-to-equity ratio | 0.14 | Low leverage |
| Equity ratio | 61.7% | Proportion of assets financed by equity |
| Return on equity (TTM) | 8.89% | Trailing twelve months |
- Low debt-to-equity (0.14) indicates limited financial leverage and greater flexibility to absorb shocks or pursue M&A, capex, or dividends.
- Declining total debt (¥120.72bn → ¥111.97bn) shows active deleveraging or scheduled repayments over FY2024-FY2025.
- Equity ratio of 61.7% and stockholders' equity of ¥795.76bn point to a durable capital structure supporting operations and investment.
- An ROE of 8.89% suggests moderate profitability on equity - acceptable given the conservative balance sheet but a metric investors may watch for improvement.
Sekisui Chemical Co., Ltd. (4204.T) - Liquidity and Solvency
- Operating cash flow (TTM): ¥122.64 billion
- Free cash flow (latest period): ¥61.71 billion (nearly doubled vs. prior period)
- Cash and cash equivalents: ¥103.57 billion
- Current ratio: 1.5 (current assets / current liabilities)
- Free cash flow to net income: >50%
- Operating cash flow to net income: strong (cash generation effectively outpacing accounting earnings)
| Metric | Value | Period / Note |
|---|---|---|
| Operating cash flow (TTM) | ¥122.64 billion | Trailing twelve months |
| Free cash flow | ¥61.71 billion | Latest reporting period (nearly doubled YoY) |
| Cash & cash equivalents | ¥103.57 billion | Latest reporting period |
| Current ratio | 1.5 | Current assets / current liabilities |
| Free cash flow / Net income | >50% | Indicates efficient conversion of earnings to free cash |
| Operating cash flow / Net income | >1.0 (strong) | Indicates robust cash generation relative to accounting profit |
- Cash generation profile: With ¥122.64bn OCF and ¥103.57bn in cash, Sekisui Chemical maintains a solid liquidity buffer to support operations, capex, and working capital needs.
- Free cash flow strength: FCF of ¥61.71bn (nearly double prior) suggests improving operational efficiency and disciplined capital spending.
- Short-term coverage: A current ratio of 1.5 signals adequate short-term solvency without excessive idle liquidity.
- Cash conversion efficiency: FCF >50% of net income and OCF-to-net-income above 1x point to high quality of earnings and resilience to non-cash accounting volatility.
Sekisui Chemical Co., Ltd. (4204.T) - Valuation Analysis
Sekisui Chemical's current valuation metrics point to a stock trading at a moderate level relative to both sales and earnings, while offering a tangible income yield for investors.- Closing price (15 Oct 2025): ¥2,739.5 - trading near 52-week high of ¥2,939.5
- Market capitalization: ≈ ¥1.06 trillion
- Price-to-Sales (P/S): 0.82 - implies the market values the company at less than 1× its annual revenues
- Trailing Twelve Months EPS: ¥143.67
- Price-to-Earnings (P/E): ≈ 19 - a moderate earnings multiple
- Dividend yield: ≈ 2.9% - steady income component for total return
| Metric | Value |
|---|---|
| Close Price (15 Oct 2025) | ¥2,739.5 |
| 52-Week High | ¥2,939.5 |
| Market Capitalization | ¥1.06 trillion |
| Price-to-Sales (P/S) | 0.82 |
| Trailing 12M EPS | ¥143.67 |
| Price-to-Earnings (P/E) | ~19 |
| Dividend Yield | ~2.9% |
- Value-oriented investors: P/S below 1 and a P/E around 19 can indicate reasonable upside if revenue stability improves or margins expand.
- Income investors: A 2.9% yield complements dividend-focused portfolios, though yield sustainability depends on earnings and cash flow.
- Growth-oriented investors: Trading near the 52-week high suggests market optimism; assess growth drivers versus the current multiple.
Sekisui Chemical Co., Ltd. (4204.T) - Risk Factors
Sekisui Chemical faces a set of interrelated operational and market risks that can affect revenue, margins and capital allocation. The items below summarize the primary near- and medium-term risk drivers, approximate sensitivities where available, and contextual notes investors should weigh alongside operational and sustainability strengths (the company has been included in the Dow Jones Sustainability Indices World Index for 13 consecutive years).
- Foreign exchange exposure: the company's overseas sales and profit translation are sensitive to JPY moves versus USD and EUR.
- High Performance Plastics (HPP): slower EV adoption and weaker EV content-per-vehicle growth reduce near-term demand for specialized polymer components.
- Medical segment: diagnostic kit and reagent demand outside Japan has softened, pressuring volumes and margins.
- Housing segment: declines in new housing starts in Japan compress product and construction-material sales.
- Trade/tariff risk: management currently anticipates minimal direct operational impact from recent U.S. tariff measures, but supply-chain pass-through risks remain.
| Risk | Primary Driver | Likelihood (near term) | Estimated P&L impact (approx.) | Mitigant / Note |
|---|---|---|---|---|
| FX volatility (JPY strength) | Stronger yen reducing translated overseas sales & margins | Medium-High | JPY -5% to -15% on consolidated operating profit per sustained 10% yen appreciation vs USD/EUR (approx. range) | Hedging programs, local cost bases, pricing adjustments |
| HPP demand shortfall | Slower EV market growth and slower EV content growth | Medium | Revenue growth compression in HPP: 0%-5% downside vs plan; operating margin pressure 1-3ppt | Portfolio diversification, focus on non-automotive HPP applications |
| Medical (diagnostics) weakness | Sluggish overseas diagnostic demand, lower test volumes | Medium | Segment profit decline 5%-12% year-on-year in weak quarters | Product mix optimization, geographic rebalancing |
| Housing sales decline | Falling new housing starts in Japan; consumer sentiment | Medium | Sales decline in Housing segment: possible -3% to -8% annually if trends persist | Shift toward renovation, non-residential products, overseas housing business |
| U.S. tariff measures | Tariff adjustments on certain imports/exports | Low-Medium | Company anticipates minimal direct impact; isolated cost increases possible (single-digit ¥bn range depending on scope) | Supply-chain adjustments, sourcing flexibility |
Additional context and operational details (history, ownership, corporate mission and how Sekisui Chemical generates revenue) can be found here: Sekisui Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
- Balance-sheet and liquidity considerations: investors should monitor working capital swings from FX and inventory in HPP/medical product pipelines; Sekisui historically maintains investment-grade metrics and capital expenditure to support growth areas.
- Sustainability & ESG tailwinds: long-standing inclusion in DJSI World (13 consecutive years) supports reputational resilience that can mitigate some market risks (procurement, customer preferences, investor base).
- Monitoring triggers for investors: sustained yen appreciation, prolonged EV demand softness, continued weakness in overseas diagnostics, or a sharp fall in Japan housing starts would be the primary triggers to reassess near-term earnings forecasts.
Sekisui Chemical Co., Ltd. (4204.T) - Growth Opportunities
Sekisui Chemical is concentrating growth efforts on three strategic fields - Electronics, Mobility, and Industrial applications - while scaling investment, R&D, and shareholder returns to capture demand for high-performance and innovative products.
- Strategic focus areas: Electronics (advanced substrates, packaging materials), Mobility (lightweight materials, battery components), Industrial applications (functional films, construction materials).
- Prioritizing high-performance product lines and platform technologies to move up the value chain and secure higher-margin sales.
- Strengthening global supply chains and customer partnerships to accelerate commercialization of next-generation solutions.
| Metric | FY2024 | FY2025 (Target / Plan) |
|---|---|---|
| Capital Expenditures | ¥70.3 billion | ¥105.0 billion |
| Research & Development | ¥43.8 billion | ¥45.0 billion |
| Net Sales | Actual FY2024 | Record high (target for FY2025) |
| Operating Profit | Actual FY2024 | Record high (target for FY2025) |
| Annual Dividend | Prior level (FY2024) | Increased annual dividend (FY2025) |
| Share Buyback | - | Significant buyback program announced (amount: disclosed by company) |
- Investment ramp: Capex increase of ~49% year-over-year (¥70.3bn → ¥105bn) to expand production capacity and new product lines.
- R&D commitment: Slight increase to ¥45.0bn to accelerate materials innovation and shorten time-to-market for core technologies.
- Profitability objectives: Management guidance aims for record net sales and operating profit in FY2025, driven by product mix improvement and scale in target markets.
- Shareholder returns: Combination of higher annual dividends and a material share buyback to enhance EPS and ROE.
For additional background on the company's evolution and strategic context, see: Sekisui Chemical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
Sekisui Chemical Co., Ltd. (4204.T) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.